Ocular Inflammatory Diseases

Molecular Pathogenesis and Immunotherapy

C E Egwuagu, L Sun, S-H Kim, I M Dambuza

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

Uveitis is a diverse group of potentially sight-threatening intraocular inflammatory diseases of infectious or autoimmune etiology and accounts for more than 10% of severe visual handicaps in the United States. Pathology derives from the presence of inflammatory cells in the optical axis and sustained production of cytotoxic cytokines and other immuneregulatory proteins in the eye. The main therapeutic goals are to down-regulate the immune response, preserve the integrity of the ocular architecture and eventually eliminate the inciting uveitogenic stimuli. Current therapy is based on topical or systemic corticosteroid with or without second line agents and serious adverse effects of these drugs are the impetus for development of less toxic and more specific therapies for uveitis. This review summarizes the pathophysiology of uveitis, molecular mechanisms that regulate the initiation and progression of uveitis and concludes with emerging strategies for the treatment of this group of potentially blinding diseases.

Original languageEnglish
Pages (from-to)517-528
Number of pages12
JournalCurrent molecular medicine
Volume15
Issue number6
DOIs
Publication statusPublished - 2015

Fingerprint

Eye Diseases
Uveitis
Immunotherapy
Poisons
Pathology
Eye Proteins
Adrenal Cortex Hormones
Cytokines
Therapeutics
Pharmaceutical Preparations
Autoimmune Diseases
Communicable Diseases
Proteins
Down-Regulation

Keywords

  • Animals
  • Autoantigens/immunology
  • Autoimmune Diseases/diagnosis
  • Autoimmunity
  • Disease Models, Animal
  • Disease Susceptibility
  • Eye Diseases/diagnosis
  • Humans
  • Immunotherapy/methods
  • Inflammation/diagnosis
  • Molecular Targeted Therapy
  • Signal Transduction
  • T-Lymphocyte Subsets/immunology

Cite this

Ocular Inflammatory Diseases : Molecular Pathogenesis and Immunotherapy. / Egwuagu, C E; Sun, L; Kim, S-H; Dambuza, I M.

In: Current molecular medicine, Vol. 15, No. 6, 2015, p. 517-528.

Research output: Contribution to journalReview article

Egwuagu, C E ; Sun, L ; Kim, S-H ; Dambuza, I M. / Ocular Inflammatory Diseases : Molecular Pathogenesis and Immunotherapy. In: Current molecular medicine. 2015 ; Vol. 15, No. 6. pp. 517-528.
@article{b36343d5489d444aa44f61bd95e81966,
title = "Ocular Inflammatory Diseases: Molecular Pathogenesis and Immunotherapy",
abstract = "Uveitis is a diverse group of potentially sight-threatening intraocular inflammatory diseases of infectious or autoimmune etiology and accounts for more than 10{\%} of severe visual handicaps in the United States. Pathology derives from the presence of inflammatory cells in the optical axis and sustained production of cytotoxic cytokines and other immuneregulatory proteins in the eye. The main therapeutic goals are to down-regulate the immune response, preserve the integrity of the ocular architecture and eventually eliminate the inciting uveitogenic stimuli. Current therapy is based on topical or systemic corticosteroid with or without second line agents and serious adverse effects of these drugs are the impetus for development of less toxic and more specific therapies for uveitis. This review summarizes the pathophysiology of uveitis, molecular mechanisms that regulate the initiation and progression of uveitis and concludes with emerging strategies for the treatment of this group of potentially blinding diseases.",
keywords = "Animals, Autoantigens/immunology, Autoimmune Diseases/diagnosis, Autoimmunity, Disease Models, Animal, Disease Susceptibility, Eye Diseases/diagnosis, Humans, Immunotherapy/methods, Inflammation/diagnosis, Molecular Targeted Therapy, Signal Transduction, T-Lymphocyte Subsets/immunology",
author = "Egwuagu, {C E} and L Sun and S-H Kim and Dambuza, {I M}",
year = "2015",
doi = "10.2174/1566524015666150731095426",
language = "English",
volume = "15",
pages = "517--528",
journal = "Current molecular medicine",
issn = "1566-5240",
publisher = "Bentham Science Publishers B.V.",
number = "6",

}

TY - JOUR

T1 - Ocular Inflammatory Diseases

T2 - Molecular Pathogenesis and Immunotherapy

AU - Egwuagu, C E

AU - Sun, L

AU - Kim, S-H

AU - Dambuza, I M

PY - 2015

Y1 - 2015

N2 - Uveitis is a diverse group of potentially sight-threatening intraocular inflammatory diseases of infectious or autoimmune etiology and accounts for more than 10% of severe visual handicaps in the United States. Pathology derives from the presence of inflammatory cells in the optical axis and sustained production of cytotoxic cytokines and other immuneregulatory proteins in the eye. The main therapeutic goals are to down-regulate the immune response, preserve the integrity of the ocular architecture and eventually eliminate the inciting uveitogenic stimuli. Current therapy is based on topical or systemic corticosteroid with or without second line agents and serious adverse effects of these drugs are the impetus for development of less toxic and more specific therapies for uveitis. This review summarizes the pathophysiology of uveitis, molecular mechanisms that regulate the initiation and progression of uveitis and concludes with emerging strategies for the treatment of this group of potentially blinding diseases.

AB - Uveitis is a diverse group of potentially sight-threatening intraocular inflammatory diseases of infectious or autoimmune etiology and accounts for more than 10% of severe visual handicaps in the United States. Pathology derives from the presence of inflammatory cells in the optical axis and sustained production of cytotoxic cytokines and other immuneregulatory proteins in the eye. The main therapeutic goals are to down-regulate the immune response, preserve the integrity of the ocular architecture and eventually eliminate the inciting uveitogenic stimuli. Current therapy is based on topical or systemic corticosteroid with or without second line agents and serious adverse effects of these drugs are the impetus for development of less toxic and more specific therapies for uveitis. This review summarizes the pathophysiology of uveitis, molecular mechanisms that regulate the initiation and progression of uveitis and concludes with emerging strategies for the treatment of this group of potentially blinding diseases.

KW - Animals

KW - Autoantigens/immunology

KW - Autoimmune Diseases/diagnosis

KW - Autoimmunity

KW - Disease Models, Animal

KW - Disease Susceptibility

KW - Eye Diseases/diagnosis

KW - Humans

KW - Immunotherapy/methods

KW - Inflammation/diagnosis

KW - Molecular Targeted Therapy

KW - Signal Transduction

KW - T-Lymphocyte Subsets/immunology

U2 - 10.2174/1566524015666150731095426

DO - 10.2174/1566524015666150731095426

M3 - Review article

VL - 15

SP - 517

EP - 528

JO - Current molecular medicine

JF - Current molecular medicine

SN - 1566-5240

IS - 6

ER -